International AIDS Conference
START: Early ART benefits all HIV-positive adults
The immediate initiation of ART in asymptomatic HIV-positive adults with a CD4+ count of more than 500 cells/mm3 significantly reduced rates of serious AIDS-related and non-AIDS–related events, according to recent findings from the Strategic Timing of Antiretroviral Treatment, or START, trial.
Opioid substitution therapy reduces HIV-, drug-related mortality among individuals with HIV, drug addiction
Study findings presented at the 2015 International AIDS Society Conference show that individuals with HIV who inject drugs had lower HIV- and drug-related mortality after receiving opioid substitution treatment.
Perinatally infected HIV patient maintains remission 11 years after therapy
Long-term remission appears to be achievable for children born with HIV-1 and treated at an early age, according to data presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
TDF2 OLE: High PrEP adherence results in zero infections
Heterosexual men and women in Botswana were highly adherent to pre-exposure prophylaxis, resulting in no new HIV infections during the course of 12 months, according to results from the the CDC’s TDF2 open-label extension trial.
Rectal gonorrhea, chlamydia do not influence transmission of HIV
Rectally colonized gonorrhea and chlamydia did not appear to impact the HIV viral loads of patients on or off ART, according to data presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
Immune cells in HIV nonprogressors metabolize cholesterol more effectively
Some HIV patients who do not receive ART may not develop AIDS for several years due to the increased efficiency in which their immune cells metabolize cholesterol, according to study data presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.